Clinical Trial Goal
To find out if belumosudil is safe and works well to prevent GVHD
You may be able to join this trial if you:
- Are 18 years old or older
- Are having a blood or marrow transplant (BMT) or have had a BMT less than 4 months ago
- Have not been treated with anti-thymocyte globulin or a similar treatment
- Have not been treated with belumosidil
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Belumosudil is a small molecule inhibitor that blocks ROCK2 on certain cells.
You’ll get:
You’ll get:
- Belumosudil – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved belumosudil to treat chronic GVHD (cGVHD) that has not gotten better with treatment. Using it in this way to prevent GVHD is new and unproven.
Locations
Sponsors
lead: Memorial Sloan Kettering Cancer Center
